$UTHR
UNITED THERAPEUTICS Corp

2021 Q4 Form 10-Q Financial Statement

#000108255421000030 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $415.2M $444.7M $380.1M
YoY Change 7.87% 17.0% -5.33%
Cost Of Revenue $34.60M $27.70M $24.00M
YoY Change -0.57% 15.42% -27.27%
Gross Profit $380.6M $417.0M $356.1M
YoY Change 8.71% 17.1% -3.36%
Gross Profit Margin 91.67% 93.77% 93.69%
Selling, General & Admin $126.9M $109.1M $66.30M
YoY Change -20.04% 64.56% -33.3%
% of Gross Profit 33.34% 26.16% 18.62%
Research & Development $82.90M $79.20M $68.70M
YoY Change -34.26% 15.28% -19.84%
% of Gross Profit 21.78% 18.99% 19.29%
Depreciation & Amortization $12.60M $12.40M $11.80M
YoY Change -3.82% 5.08% -7.09%
% of Gross Profit 3.31% 2.97% 3.31%
Operating Expenses $209.8M $79.20M $68.70M
YoY Change -26.33% 15.28% -19.84%
Operating Profit $170.8M $228.7M $221.1M
YoY Change 161.56% 3.44% 20.56%
Interest Expense -$26.90M $4.600M $4.900M
YoY Change -49.63% -6.12% -58.12%
% of Operating Profit -15.75% 2.01% 2.22%
Other Income/Expense, Net -$2.400M -$24.30M -$2.100M
YoY Change -102.34% 1057.14% -87.27%
Pretax Income $140.5M $204.4M $219.0M
YoY Change 22.81% -6.67% 31.22%
Income Tax $28.30M $41.70M $47.80M
% Of Pretax Income 20.14% 20.4% 21.83%
Net Earnings $112.2M $162.7M $171.2M
YoY Change 13.56% -4.96% 29.31%
Net Earnings / Revenue 27.02% 36.59% 45.04%
Basic Earnings Per Share $3.62 $3.86
Diluted Earnings Per Share $2.342M $3.42 $3.84
COMMON SHARES
Basic Shares Outstanding 45.04M shares 44.90M shares 44.40M shares
Diluted Shares Outstanding 47.60M shares 44.60M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.931B $2.000B $1.581B
YoY Change 5.22% 26.57% 0.67%
Cash & Equivalents $894.8M $908.5M $670.2M
Short-Term Investments $1.036B $1.092B $910.3M
Other Short-Term Assets $100.4M $76.00M $47.50M
YoY Change 13.7% 60.0% -44.57%
Inventory $93.80M $96.70M $87.90M
Prepaid Expenses
Receivables $198.7M $212.8M $152.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.324B $2.386B $1.868B
YoY Change 7.22% 27.71% -3.37%
LONG-TERM ASSETS
Property, Plant & Equipment $780.9M $726.7M $736.4M
YoY Change 6.74% -1.32% 8.57%
Goodwill $28.00M $28.00M $28.00M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $1.650B $1.509B $1.228B
YoY Change 43.52% 22.91% 68.06%
Other Assets $108.2M $109.0M $165.4M
YoY Change -36.32% -34.1% -28.4%
Total Long-Term Assets $2.846B $2.663B $2.543B
YoY Change 16.25% 4.72% 23.08%
TOTAL ASSETS
Total Short-Term Assets $2.324B $2.386B $1.868B
Total Long-Term Assets $2.846B $2.663B $2.543B
Total Assets $5.169B $5.049B $4.411B
YoY Change 12.01% 14.46% 10.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $210.5M $177.1M
YoY Change -7.32% 18.86% 9.93%
Accrued Expenses $170.8M
YoY Change -6.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $305.4M $320.0M $258.9M
YoY Change -5.54% 23.6% -44.9%
LONG-TERM LIABILITIES
Long-Term Debt $800.0M $800.0M $800.0M
YoY Change 0.0% 0.0% 6.67%
Other Long-Term Liabilities $104.8M $99.20M $69.20M
YoY Change 8.6% 43.35% 8.29%
Total Long-Term Liabilities $104.8M $99.20M $69.20M
YoY Change 8.6% 43.35% 8.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $305.4M $320.0M $258.9M
Total Long-Term Liabilities $104.8M $99.20M $69.20M
Total Liabilities $1.210B $1.219B $1.128B
YoY Change -0.79% 8.08% -12.13%
SHAREHOLDERS EQUITY
Retained Earnings $4.315B $4.203B $3.740B
YoY Change 12.39% 12.36% 14.29%
Common Stock $2.246B $2.226B $2.126B
YoY Change 4.5% 4.69% 4.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.959B $3.830B $3.283B
YoY Change
Total Liabilities & Shareholders Equity $5.169B $5.049B $4.411B
YoY Change 12.01% 14.46% 10.29%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $112.2M $162.7M $171.2M
YoY Change 13.56% -4.96% 29.31%
Depreciation, Depletion And Amortization $12.60M $12.40M $11.80M
YoY Change -3.82% 5.08% -7.09%
Cash From Operating Activities $174.6M $185.6M $250.9M
YoY Change 38.35% -26.03% 35.33%
INVESTING ACTIVITIES
Capital Expenditures -$70.60M -$23.30M -$15.80M
YoY Change 473.98% 47.47% 16.18%
Acquisitions
YoY Change
Other Investing Activities -$125.2M -$212.6M -$255.9M
YoY Change 143.11% -16.92% -10.24%
Cash From Investing Activities -$195.8M -$235.9M -$271.7M
YoY Change 206.9% -13.18% -9.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.500M 16.60M 5.600M
YoY Change 22.95% 196.43% -111.59%
NET CHANGE
Cash From Operating Activities 174.6M 185.6M 250.9M
Cash From Investing Activities -195.8M -235.9M -271.7M
Cash From Financing Activities 7.500M 16.60M 5.600M
Net Change In Cash -13.70M -33.70M -15.20M
YoY Change -120.0% 121.71% -90.59%
FREE CASH FLOW
Cash From Operating Activities $174.6M $185.6M $250.9M
Capital Expenditures -$70.60M -$23.30M -$15.80M
Free Cash Flow $245.2M $208.9M $266.7M
YoY Change 77.04% -21.67% 34.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001082554
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-26301
dei Entity Registrant Name
EntityRegistrantName
United Therapeutics Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-1984749
dei Entity Address Address Line1
EntityAddressAddressLine1
1040 Spring Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Silver Spring
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20910
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
608-9292
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
UTHR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45036501 shares
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45036501 shares
CY2021Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
44700000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158100000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
908500000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
738700000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1091900000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1096300000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
212800000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
157400000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
96700000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
86500000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
76000000.0 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
88300000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
2385900000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2167200000 USD
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1508700000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1149600000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
726700000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
731600000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
273900000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
238600000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000000.0 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
169900000 USD
CY2021Q3 us-gaap Assets
Assets
5048900000 USD
CY2020Q4 us-gaap Assets
Assets
4615000000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
210500000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
187000000.0 USD
CY2021Q3 uthr Share Tracking Award Plans
ShareTrackingAwardPlans
83500000 USD
CY2020Q4 uthr Share Tracking Award Plans
ShareTrackingAwardPlans
96800000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000000.0 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39500000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
320000000.0 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
323300000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
800000000.0 USD
CY2020Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
800000000.0 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99200000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
96500000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
1219200000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
1219800000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71640713 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71126314 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45021497 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44507098 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
700000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
700000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2225500000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2148700000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20100000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14200000 USD
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26619216 shares
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26619216 shares
CY2021Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2579200000 USD
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2579200000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4202800000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3839200000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3829700000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3395200000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5048900000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4615000000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
444700000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1270300000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
444700000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1270300000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27700000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000000.0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
87900000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
73300000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79200000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68700000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
457200000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231600000 USD
CY2021Q3 uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
109100000 USD
CY2020Q3 uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
66300000 USD
uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
339100000 USD
uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
265200000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
216000000.0 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
159000000.0 USD
us-gaap Costs And Expenses
CostsAndExpenses
884200000 USD
us-gaap Costs And Expenses
CostsAndExpenses
570100000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
228700000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221100000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
386100000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
528300000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3800000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6400000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
12500000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
23600000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
4600000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4900000 USD
us-gaap Interest Expense
InterestExpense
13900000 USD
us-gaap Interest Expense
InterestExpense
18700000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23500000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
71000000.0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
400000 USD
CY2021Q3 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
0 USD
CY2020Q3 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
3500000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
2300000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
9100000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24300000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2100000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67300000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3800000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
204400000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
219000000.0 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
453400000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
524500000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41700000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47800000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89800000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108500000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
162700000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
us-gaap Net Income Loss
NetIncomeLoss
363600000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.62
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.43
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.42
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.37
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44900000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44100000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47600000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44400000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
162700000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
us-gaap Net Income Loss
NetIncomeLoss
363600000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
CY2021Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
0 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
200000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
200000 USD
CY2021Q3 uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
100000 USD
CY2020Q3 uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
300000 USD
uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
400000 USD
uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
900000 USD
CY2021Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-100000 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-300000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-600000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-1100000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1600000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2700000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6500000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8600000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1500000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2400000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5900000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9700000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
161200000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
168800000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
357700000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
425700000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3639500000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
162700000 USD
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1600000 USD
CY2021Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-100000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2800000 USD
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
200000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000000.0 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12400000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3829700000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3093700000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2700000 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-300000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2200000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
100000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3500000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15000000.0 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3283100000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3395200000 USD
us-gaap Net Income Loss
NetIncomeLoss
363600000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-6500000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-600000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5600000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
10600000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42300000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39500000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3829700000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2780400000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8600000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50200000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-1100000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4700000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3600000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25900000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50800000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3283100000 USD
us-gaap Net Income Loss
NetIncomeLoss
363600000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
37300000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
93800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
70100000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
2300000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
9100000 USD
uthr Impairment Of Intangible Assets
ImpairmentOfIntangibleAssets
113400000 USD
uthr Impairment Of Intangible Assets
ImpairmentOfIntangibleAssets
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
18200000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5400000 USD
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
91900000 USD
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
3400000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-28000000.0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
55400000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
900000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7400000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11100000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
22000000.0 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
27900000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
100300000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-64300000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
423600000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
629500000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000000.0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2400000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1398400000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1698800000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1003500000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
964900000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
45100000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
76500000 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
108900000 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
27300000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-291100000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-674700000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
50000000.0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42300000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25900000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5600000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4700000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10600000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3600000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37300000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23000000.0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169800000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68200000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
738700000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
738400000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
908500000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
670200000 USD
us-gaap Interest Paid Net
InterestPaidNet
12100000 USD
us-gaap Interest Paid Net
InterestPaidNet
16600000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
130100000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
62300000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000000.0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4400000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business Description<div><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. On September 30, 2021, we converted to a Delaware public benefit corporation, with the express public benefit purpose to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to market the following therapies: Tyvaso</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tyvaso</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Remodulin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Injection (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Orenitram</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Orenitram</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Unituxin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Unituxin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and Adcirca</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Adcirca</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We also derive revenues outside the United States from sales of Tyvaso, Remodulin, and Unituxin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for complete financial statements. Certain prior year amounts have been reclassified to conform to the current year presentation. In the operating activities section of our consolidated statements of cash flows, we reclassified a portion of the prior period amount within </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other assets and liabilities</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to the line items </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">realized gain on sale of equity securities </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> other</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to conform with the current period presentation. In the investing activities section of our consolidated statements of cash flows, we reclassified the prior period amount within </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">sales/maturities of available-for-sale investments</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to the line items </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">maturities of available-for-sale investments</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">sales of available-for-sale investments</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to conform with the current period presentation. These consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 24, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In our management’s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of September 30, 2021 and December 31, 2020, our statements of operations, comprehensive income, and stockholders’ equity for the three- and nine-month periods ended September 30, 2021 and 2020, and our statements of cash flows for the nine-month periods ended September 30, 2021 and 2020. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'DIN Regular',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'DIN Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Adopted During the Period</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) issued Accounting Standards Update (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) No. 2019-12, </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> which simplifies the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, Income Taxes, and also improves consistency of application by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. We adopted the new standard on January 1, 2021, with no material impact on our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Investments-Equity Securities (Topic 321), Investments–Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)–Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force) </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ASU 2020-01</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which addresses the accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We adopted the new standard on January 1, 2021, with no material impact on our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'DIN Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ASU 2020-04</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which provides optional expedients and exceptions to lessen the burden of accounting for contract modifications and hedging relationships that reference LIBOR or other reference rates that could be discontinued due to reference rate reform. ASU 2020-04 became effective immediately and may be applied through December 31, 2022. We are currently evaluating the impact of the expedients and exceptions of this new standard on our accounting for our credit agreement, which references LIBOR.</span></div>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2616600000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5500000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1100000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2621000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2621000000 USD
CY2021Q1 us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
108900000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2233600000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000000.0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
100000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2246500000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2246500000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
1109200000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
1112300000 USD
CY2021Q3 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughThreeAmortizedCostBasis
1507400000 USD
CY2021Q3 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Year Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughYearThreeFairValue
1508700000 USD
CY2021Q3 uthr Contractual Maturities Of Available For Sale Debt Securities Amortized Cost Basis
ContractualMaturitiesOfAvailableForSaleDebtSecuritiesAmortizedCostBasis
2616600000 USD
CY2021Q3 uthr Contractual Maturities Of Available For Sale Securities Debt Securities
ContractualMaturitiesOfAvailableForSaleSecuritiesDebtSecurities
2621000000 USD
CY2021Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
99400000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
78400000 USD
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
91900000 USD
CY2021Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
91900000 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
27300000 USD
uthr Change In Fair Value Amount Of Contingent Consideration Asset
ChangeInFairValueAmountOfContingentConsiderationAsset
1600000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15900000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
18400000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
31300000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
29500000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
49500000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
38600000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
96700000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
86500000 USD
CY2021Q3 us-gaap Goodwill Gross
GoodwillGross
28000000.0 USD
CY2021Q3 us-gaap Goodwill
Goodwill
28000000.0 USD
CY2020Q4 us-gaap Goodwill Gross
GoodwillGross
28000000.0 USD
CY2020Q4 us-gaap Goodwill
Goodwill
28000000.0 USD
CY2021Q3 uthr Goodwill And Other Intangibles Assets Gross
GoodwillAndOtherIntangiblesAssetsGross
50200000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5500000 USD
CY2021Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
44700000 USD
CY2020Q4 uthr Goodwill And Other Intangibles Assets Gross
GoodwillAndOtherIntangiblesAssetsGross
163600000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5500000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158100000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067900000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1040900000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
341200000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
309300000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
726700000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
731600000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
18200000 USD
CY2021Q3 uthr Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2 plan
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24600000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-12500000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93800000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70100000 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
31300000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
162700000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
us-gaap Net Income Loss
NetIncomeLoss
363600000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44900000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44100000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2700000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
200000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2300000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
300000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47600000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44400000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.62
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.12
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1270300000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.43
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.42
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.37
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7500000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7400000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.20
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2021Q3 uthr Unrecognized Tax Benefits Including Interest And Penalties
UnrecognizedTaxBenefitsIncludingInterestAndPenalties
5300000 USD
CY2020Q4 uthr Unrecognized Tax Benefits Including Interest And Penalties
UnrecognizedTaxBenefitsIncludingInterestAndPenalties
4900000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
444700000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27700000 USD
CY2021Q3 uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
417000000.0 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000000.0 USD
CY2020Q3 uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
356100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1270300000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
87900000 USD
uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
1182400000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
73300000 USD
uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
1025100000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
444700000 USD
CY2021Q3 uthr Number Of Distributors
NumberOfDistributors
3 distributor
uthr Number Of Distributors
NumberOfDistributors
3 distributor
uthr Number Of Distributors
NumberOfDistributors
3 distributor
CY2020Q3 uthr Number Of Distributors
NumberOfDistributors
3 distributor
CY2021Q3 uthr Number Of Distributors
NumberOfDistributors
3 distributor
CY2020Q3 uthr Number Of Distributors
NumberOfDistributors
3 distributor
uthr Number Of Distributors
NumberOfDistributors
3 distributor
uthr Number Of Distributors
NumberOfDistributors
3 distributor

Files In Submission

Name View Source Status
0001082554-21-000030-index-headers.html Edgar Link pending
0001082554-21-000030-index.html Edgar Link pending
0001082554-21-000030.txt Edgar Link pending
0001082554-21-000030-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
uthr-20210930.htm Edgar Link pending
uthr-20210930.xsd Edgar Link pending
uthr-20210930_cal.xml Edgar Link unprocessable
uthr-20210930_def.xml Edgar Link unprocessable
uthr-20210930_htm.xml Edgar Link completed
uthr-20210930_lab.xml Edgar Link unprocessable
uthr-20210930_pre.xml Edgar Link unprocessable
uthrex31109302021.htm Edgar Link pending
uthrex31209302021.htm Edgar Link pending
uthrex32109302021.htm Edgar Link pending
uthrex32209302021.htm Edgar Link pending